BRCA1 and neoplasm: Accumulation of replication‐associated DNA damage is characteristic of BRCA1/2‐mutated tumours and increases their vulnerability to targeted therapies, with inhibitors of poly(ADP‐ribose) polymerases (PARPs) as a prominent example (Lord & Ashworth, 2016).